Stock Analysis of Evotec SE ADR (EVO) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code EVO
Close 5.25
Change -0.240 / 4.37 %
Volume 72144.00
Vol Change 16316.00 / 29.23 %
IndustryDrug Manufacturers-Specialty & Generic
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Low Growth Stock
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Very Low Stability Stock


Fundamental View of Evotec SE ADR
PE (TTM)

-14.33

Very Poor
Price / Book

1.20

Very Good
Price / Sales

1.72

Good
Piotroski F Score

5.0

Indecisive
Market Cap

1860.45 M

Enterprise Value

1498.62 M

ROA (TTM)

-4.28

Very Poor
ROE (TTM)

-8.37

Very Poor
Net Margin (TTM)

-12.02

Very Poor
Revenue

9.23 %

820802 K
Net Profit

45.93 %

-94983.00 K
Debt to Equity

0.133

Excellent
Altman Z Score

0.841

Poor
Quick Ratio

1.88

Indecisive
Cash Ratio

1.30

Indecisive


Highs/Lows of Evotec SE ADR
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week5.15 1.94 % 1.54 % 5.685.2215-May-2417-May-24
Two Week5.27 0.380 % 3.42 % 5.685.1315-May-2407-May-24
One Month7.24 27.49 % 5.60 % 7.774.870123-Apr-2425-Apr-24
Three Month7.36 28.67 % 5.95 % 7.984.870108-Apr-2425-Apr-24
Six Months10.09 47.97 % 17.48 % 11.99994.870128-Dec-2325-Apr-24
One year10.74 51.12 % 27.52 % 13.49244.870125-Jul-2325-Apr-24
Two year13.07 59.83 % 29.70 % 13.49244.870125-Jul-2325-Apr-24
Five year12.9975 59.61 % 85.46 % 13.49244.870125-Jul-2325-Apr-24
Ten year2.33 125.32 % 182.41 % 26.571.56521-Oct-2116-Oct-14


Technical View of Evotec SE ADR
RSI

37.58

Neutral
MACD

-0.382

Bullish
ADX

26.09

Mild Bearish
Super Trend

5.94

Mild Bearish
Williams %R

-78.18

Neutral
CCI

-34.40

Neutral


EMA 5

5.40

Strong Bearish
EMA 15

5.52

Neutral
EMA 50

6.41

Mild Bearish
EMA 100

7.29

Strong Bearish
SMA 100

7.48

Strong Bearish
SMA 200

8.93

Strong Bearish
SMA 5 / 20

5.46 / 5.50

Mild Bearish
SMA 15 / 50

5.30 / 6.61

Strong Bearish
SMA 50 / 200

6.61 / 8.93

Strong Bearish




Charts of Evotec SE ADR


Returns of Evotec SE ADR with Peers
Period / StockEVOAMPHAMRXTLRYKROS
1 Week1.94%3.01%2.40%2.59%-3.67%
1 Mth-27.49%8.56%25.02%15.12%-11.79%
3 Mth-28.67%-19.57%15.59%3.13%-12.12%
6mth-47.97%-22.15%50.55%8.20%72.66%
1 Year-51.12%1.19%227.88%-17.84%13.16%
2 Year-59.83%21.01%84.32%-61.48%13.31%
5 Years-59.61%98.36%-20.42%-95.66%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Evotec SE ADR with Peers
Ratio / StockEVOAMPHAMRXTLRYKROS
PE-14.3314.20-10.89-1145.63-2426.37
P/B1.203.6118.63148.411102.94
ROA-4.2811.40-3.78-9.41-41.68
ROE-8.3725.40-171.16-9.71-45.46
Debt To Equity0.1330.929125.170.0680.0030
Revenue820802 K
9.23 % 		601313 K
20.51 % 		2393.61 M
8.20 % 		627124 K
0.199 % 		151000
99.25 %
Net Income-94983.00 K
45.93 % 		135291 K
48.04 % 		-83993.00 K
35.38 % 		-1443.00 M
202.64 % 		-152992.00 K
46.15 %


Technicals of Evotec SE ADR with Peers
Technical / StockEVOAMPHAMRXTLRYKROS-
ADX26.0927.2935.1833.2525.81
CMF0.1690.0760.373-0.153-0.223
MFI77.5746.7685.4855.9442.85
RSI37.5858.3465.5149.0636.33
MACD Abv SignalTrueTrueTrueTrueFalse
Price Above 50 MAFalseTrueTrueFalseFalse-
Price Above 200 MAFalseFalseTrueFalseTrue-


About : Evotec SE ADR

Address : Essener Bogen 7, Hamburg, Germany, 22419
Tel : 49 40 560 81 0
URL : https://www.evotec.com
Code : EVO, ISIN : US30050E1055, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 04_Dec_2009
Employee Count : 5061

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.


Note : All Data Generated at the End of Trading Hours (EOD Data)